Amphastar Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 04/23/2024
Amphastar Pharmaceuticals Stock Forecast and Price Target
Amphastar Pharmaceuticals has an average price target of $62.00 recently offered by notable experts for 2024, which would represent a potential upside of approximately 54.34% from the last closing price in April, 2024 if reached. This potential increase is based on a high estimate of $71.00 and a low estimate of $50.00. If you are not interested in AMPH stock, you may be interested in its competitors.
54.34% Upside
Amphastar Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Amphastar Pharmaceuticals's Price has gone down from $24.10 to $0.00 – a 100.00% drop. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach $124.25 – an increase of 100.00%. Over the next seven years, experts anticipate that Fair Value growth for Amphastar Pharmaceuticals will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$731.33 | Buy/Sell | $636.99 | 14.52% |
| NOVO B Stock Forecast | Novo Nordisk A/S | Outperform |
12
|
kr875.30 | Buy/Sell | kr696.07 | 9.68% |
| SUNPHARMA Stock Forecast | Sun Pharmaceutical Industries | Outperform |
8
|
Rp1.54k | Buy/Sell | Rp1.52k | 2.92% |
| TEVA Stock Forecast | Teva Pharmaceutical Industries | Outperform |
12
|
$12.88 | Buy/Sell | $11.59 | 24.22% |
| HIK Stock Forecast | Hikma Pharmaceuticals PLC | Outperform |
18
|
£18.18 | Buy/Sell | £28.11 | 62.71% |
Amphastar Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Revenue for Amphastar Pharmaceuticals has grown by 42.63%, going from $349.85M to $498.99M. In the coming year, analysts are expecting an increase in Revenue, predicting it will reach $786.38M – an increase of 57.59%. Over the next seven years, experts anticipate that Revenue growth for Amphastar Pharmaceuticals will be 100.75%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ZEAL Stock Forecast | Zealand Pharma A/S | Outperform |
8
|
kr581.50 | Buy/Sell | kr357.00 | 40.15% |
| HALO Stock Forecast | Halozyme Therapeutics | Outperform |
11
|
$38.71 | Buy/Sell | $47.50 | 26.58% |
| PBH Stock Forecast | Prestige Consumer Healthcare | Outperform |
16
|
$69.80 | Buy/Sell | $71.50 | 6.73% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BHC Stock Forecast | Bausch Health Companies | Hold |
15
|
$8.45 | Buy/Sell | $9.50 | 12.43% |
| AMRX Stock Forecast | Amneal Pharmaceuticals | Outperform |
16
|
$5.37 | Buy/Sell | $6.13 | 39.66% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$29.71 | Buy/Sell | $41.00 | 34.63% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ANIP Stock Forecast | ANI Pharmaceuticals | Buy |
13
|
$65.62 | Buy/Sell | $69.75 | 21.91% |
| XERS Stock Forecast | Xeris Biopharma Holdings | Buy |
6
|
$1.78 | Buy/Sell | $4.60 | 166.85% |
| EBS Stock Forecast | Emergent BioSolutions | Outperform |
16
|
$2.16 | Buy/Sell | $5.00 | 131.48% |
Amphastar Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Amphastar Pharmaceuticals's EBITDA has grown, increasing from $34.78M to $132.73M – an increase of 281.63%. For next year, the 2 analysts predict EBITDA of $295.62M, which would mean an increase of 122.72%. Over the next seven years, the pros' prediction is EBITDAof $403.79M, which would mean a seven-year growth forecast of 204.22%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ASRT Stock Forecast | Assertio Holdings | Buy |
8
|
$0.87 | Buy/Sell | $3.50 | 244.83% |
| EGRX Stock Forecast | Eagle Pharmaceuticals | - |
14
|
$4.55 | Buy/Sell | $17.00 | -100.00% |
| OPNT Stock Forecast | Opiant Pharmaceuticals | - |
10
|
$20.77 | Buy/Sell | $21.00 | -100.00% |
Amphastar Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
Amphastar Pharmaceuticals's EBIT has increased by 711.32% In the last two years, going from $13.25M to $107.50M. In the next year, analysts expect EBIT to reach $260.39M – an increase of 142.22%. For the next seven years, the forecast is for EBIT to grow by 243.73%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LCI Stock Forecast | Lannett Company | - |
10
|
$0.03 | Buy/Sell | $4.00 | -100.00% |
| ACOR Stock Forecast | Acorda Therapeutics | - |
5
|
$0.43 | Buy/Sell | $200.00 | -100.00% |
| ENDP.Q Stock Forecast | Endo International | - |
14
|
$0.00 | Buy/Sell | $1.33 | 0.00% |
Amphastar Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Amphastar Pharmaceuticals's EPS has gone down from $0.64 to $0.00 – a 100.00% drop. In the coming year, analysts are expecting an increase in EPS, predicting it will reach $3.30 – an increase of 100.00%. Over the next seven years, experts anticipate that EPS growth for Amphastar Pharmaceuticals will be 100.00%.
Site Navigation
.jpg)